Reach Pharmaceuticals
Providing Emerging Therapeutics Globally
Company
News
November 2023: The TGA approved an alternative to the 25 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until March 31, 2024. Contact Us for more details.
​
October 2023: Dexrazoxane is granted Orphan Drug Designation by the TGA in Australia. Contact Us for more details.
October 2023: Reach Pharmaceuticals launches CARBOPROST-REACH solution for injection in Australia. The product is the first carboprost formulation launched since the innovator brand was discontinued in 2013. Contact Us for more details.
​
June 2023: Cefuroxime 125mg/5 mL granules for oral suspension is now listed on the PBS. Contact Us for more details.
​
September 2023: The TGA approved the supply of NELARABINE-REACH solution for injection through early access to a medicine under evaluation for inclusion on the ARTG in Australia. Contact Us for more details.
​
August 2023: The TGA approved an alternative to the 25 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until September 30, 2023. Contact Us for more details.
​
August 2023: The TGA approved an alternative to the 50 micrograms/24 hours estradiol transdermal patches product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until September 30, 2023. Contact Us for more details.
July 2023: The TGA approved CYCLOPHOSPHAMIDE-REACH powder for injection. Contact Us for more details.
​
July 2023: The TGA approved two alternatives to the glucagon 1mg powder and solvent for solution for injection product currently in shortage under S19A of the Therapeutic Goods Act, 1989 until October 31, 2023. Contact Us for more details.
​
July 2023: The TGA approved alternatives to the doxepin hydrochloride 25 mg and 50mg capsules products currently in shortage under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023 and 30 September 2023 respectively. Contact Us for more details.
​
June 2023: The TGA approved CARBOPROST-REACH solution for injection. Contact Us for more details.
June 2023: The TGA approved the importation of an alternative to cefuroxime 125mg/5 mL granules for oral suspension under S19A of the Therapeutic Goods Act, 1989 until June 30, 2024. Contact Us for more details.
​
May 2023: The TGA approved the importation of an alternative to the sugar free 40 mg trimethoprim and 200 mg sulfamethoxazole oral liquid in shortage under S19A of the Therapeutic Goods Act, 1989 until August 31, 2023. Contact Us for more details.
​
April 2023: The TGA approved the importation of an alternative to captopril 25 mg/5 mL oral solution under S19A of the Therapeutic Goods Act, 1989 until April 30, 2024. Contact Us for more details.
April 2023: The TGA approved the importation of an alternative to prochlorperazine mesilate 12.5mg/1mL injection ampoule under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023. Contact Us for more details.
​
March 2023: The TGA approved the importation of DISTACLOR cefaclor 250 mg/5 mL granules for oral suspension (UK) under S19A of the Therapeutic Goods Act, 1989 until November 30, 2023.
​
January 2023: The TGA approved the importation of KEFORAL cefalexin 250 mg/5 mL granules for oral suspension under S19A of the Therapeutic Goods Act, 1989 until December 31, 2023.
​
December 2022: REACH received Orphan Drug Designation for Nelarabine for infusion from the TGA in Australia.
​
December 2022: REACH received approval for ROMIDEPSIN-REACH powder for injection in Australia.
December 2022: The TGA approved the importation of AMOXICILLIN 125MG/5ML ORAL SUSPENSION SUGAR FREE BP (ATHLONE) under S19A of the Therapeutic Goods Act, 1989 until June 30, 2023.
​
November 2022: The TGA approved the importation of METRONIDAZOLE 200MG/5ML ORAL SUSPENSION (ROSEMONT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.
​
August, 2022: The TGA approved the importation of OLENA fluoxetine hydrochloride 20 mg dispersible tablet under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022.
​
August, 2022: The TGA approved the importation of AMOXICILLIN 250MG/5ML ORAL SUSPENSION SUGAR FREE BP (KENT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.
​
​July, 2022: Reach received Orphan Drug Designation for Carboprost for injection from the Therapeutic Goods Administration.
June, 2022: Our online store is now live! Visit the Shop tab to order the available products or click here.
​
​June, 2022: Reach is pleased to announce the approval of THIOTEPA-REACH 15 mg powder for injection and THIOTEPA-REACH 100 mg powder for injection in Australia. For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here
​
​June, 2022: Reach is pleased to announce the launch of Cipla Isoprenaline for injection 0.2mg/mL, 25 ampoules and Cipla Isoprenaline for injection 1mg/5mL, 10 ampoules. For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here
June, 2022: Reach is pleased to announce the launch of Metabolics Potassium Citrate 1.08g modified release tablets. For more details please contact us on sales@reach-pharma.com. The CMI is available here
​
January, 2022: The TGA approved the importation of Xylanaest 1% with Epinephrine 1:200,000 5ml ampoule under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022.
​
December, 2021: The TGA approved the importation of Thiotepa for Injection, USP 15 mg AND Thiotepa for injection Injection, USP 100 mg under S19A of the Therapeutic Goods Act, 1989 until September 30, 2022.
​
October, 2020: Icatibant 30mg/3mL is available from Reach for supply to hospitals in Australia. The product was listed on the PBS in October.​​ The PI is available from the TGA website, click here
​
June, 2020: The TGA approved the importation of Isoproterenol Hydrochloride Injection, USP 1 mg/5 mL solution for injection ampoule under S19A of the Therapeutic Goods Act, 1989 until April 30, 2022.
Source & Supply
We are actively involved in the pharmaceuticals market, to source and supply treatments globally
Market pathways
Over15 years experience in new product launches spanning from regulatory affairs to customer identification
Consultancy
Business planning, product registration and market insight
Expertise
Products
Available on the Market or approved for supply
Product Product Details
THIOTEPA-REACH for injection 15 mg PI, CMI
THIOTEPA-REACH for injection 100 mg PI, CMI
ROMIDEPSIN-REACH powder for injection PI, CMI
CARBOPROST-REACH solution for injection PI, CMI
CYCLOPHOSPHAMIDE-REACH 500 mg for injection Contact Us
CYCLOPHOSPHAMIDE-REACH 1000 mg for injection Contact Us
NELARABINE-REACH 250 mg/5 mL solution for injection-S19A Contact Us
METABOLICS POTASSIUM CITRATE 10 MR tablets 1.08g Contact Us
METABOLICS L-Carnitine 500 mg capsules Contact Us
​
CIPLA ISOPRENALINE Isoprenaline for injection 0.2mg/mL PI, CMI
CIPLA ISOPRENALINE Isoprenaline for injection 1mg/5mL PI, CMI
CIPLA ICATIBANT pre-filled syringe 30mg/3mL PI, CMI
FOSAPREPITANT MSN 150 mg powder for injection PI, CMI
MSN CABAZITAXEL injection 60mg/1.5mL PI, CMI
DUKAL povidone iodine 10% - S19A Contact Us
ZINNAT cefuroxime 125mg/5 mL oral suspension - S19A
CAPTOPRIL SYRIMED 25 mg/ 5 mL oral solution - S19A
KEFORAL 125 mg/5 mL granules for suspension - S19A
Doxepin hydrochloride 25mg capsules, USP (Amneal) - S19A
Doxepin hydrochloride 50mg capsules, USP (Amneal) - S19A
GlucaGen HypoKit glucagon 1mg powder and solvent for
solution for injection (Switzerland) - S19A
GlucaGen HypoKit glucagon 1mg powder and solvent for
solution for injection (Italy) - S19A
ESTRAMON 25 micrograms/24 hours estradiol transdermal
patches (Germany) - S19A
CO-TRIMOXAZOLE sulfamethoxazole and trimethoprim
40mg/200mg per 5mL paediatric suspension (Aspen)
Available Under Special Circumstances Contact Us
Product
REAURO001
REAURO002
REAURO003
PRE001
TBRIFISO001
TBRIFISOPYR001
PYR001
CLOF001
CYC001
LEV001
PAS001
PRO001
Under Development or Regulatory Evaluation Contact Us Nelarabine for infusion
REACAF002
REACARM005
REACAR006
REAOXY001
REAFRU001
Reach Pharmaceuticals is an Australian privately-owned company with a focus on marketing of innovative products that have a first to market advantage. The company also registers and supplies complex generics and other therapeutic goods formulated based on demand from clinicians.
Our pipeline includes thiotepa, potassium citrate, isoprenaline, icatibant, urokinase, carboprost and romidepsin to name a few. We have the capabilities to pursue compassionate supplies of products to fulfil shortages and manage the entire process from product identification to generation of sales.
The company is a leader in the hospital pharmaceuticals space and holds majority market share for all the products launched to date whether registered or supplied under compassionate supplies. We also have an interest in distribution of branded products and will be pursuing launch of new products in the future.
About Us
Contact Us
Location:
Ground Floor, Corporate One
84 Hotham Street
Preston VIC 3072
​
Email:
For medical enquiries:
​
Phone:
General & Sales: 0422 429 648
Medical enquiries or reporting adverse events: 1800 505 306
